To create a shorter KCCQ, we used data from 2 randomized trials and one observational cohort study of HF patients, all of which have been previously used to demonstrate some of the psychometric properties of the full instrument: (1) the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) study, a randomized trial of patients hospitalized with HF;23 (link) (2) the Eplerenone Post-AMI Heart Failure Efficacy and Survival (EPHESUS) study, a randomized trial of patients with HF complicating acute myocardial infarction;24 (link) and (3) the KCCQ Interpretability Study (KCCQINT), a 14-center North American cohort study of patients presenting at outpatient HF clinics.13 (link) Descriptions of the studies and KCCQ samples used in the various analyses are provided in Figure. Using these studies, we derived and validated the short KCCQ within 3 distinct clinical settings: (1) stable HF, (2) outpatient HF clinic visits, and (3) acute HF recovery (1 week after hospitalization for decompensated HF). Within each setting, data were split randomly into 2 50% samples, one for derivation (ie, item selection) and one for validation of the final short-version scores. All studies underwent IRB approval before their conduct, and each patient signed informed consent to participate.
>
Chemicals & Drugs
>
Organic Chemical
>
Eplerenone
Eplerenone
Eplerenone is a synthetic steroidal antimineralocorticoid agent used to treat hypertension and heart failure.
It selectively blocks the aldosterone receptor, preventing the binding and activation of aldosterone, a hormone that regulates fluid and electrolyte balance.
Eplerenone has been shown to improve survival and reduce the risk of cardiovascular events in patients with left ventricular dysfunction and heart failure following myocardial infarction.
Reasearch related to Eplerenone can be optimizied using PubCompare.ai, an AI-driven protocol comparison tool that helps locate and analyze relevant studies from literature, pre-prints, and patents to ensure reproducility and identify the best research approaches.
It selectively blocks the aldosterone receptor, preventing the binding and activation of aldosterone, a hormone that regulates fluid and electrolyte balance.
Eplerenone has been shown to improve survival and reduce the risk of cardiovascular events in patients with left ventricular dysfunction and heart failure following myocardial infarction.
Reasearch related to Eplerenone can be optimizied using PubCompare.ai, an AI-driven protocol comparison tool that helps locate and analyze relevant studies from literature, pre-prints, and patents to ensure reproducility and identify the best research approaches.
Most cited protocols related to «Eplerenone»
Clinic Visits
Congestive Heart Failure
Eplerenone
Hospitalization
Myocardial Infarction
North American People
Patients
Psychometrics
Tolvaptan
Vasopressin Antagonist
All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Publication No. 85–23, revised 1985). All procedures were approved by the Regierung von Unterfranken (Würzburg, Germany; permit No. 54–2531.01-15/07) and by the Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit (Oldenburg, Germany; permit No. 33.12-42502-04-11/0644 and 33.9-42502-04-13/1124). Adult Nr3c2tm2Gsc (MRflox, WT controls), Nr3c2tm2GscLyz2tm1(cre)lfo/J (MRLysMCre), and C57Bl/6 mice of both sexes were used in this study. Liposome-encapsulated RU28318 (2 µmol/kg) or liposome-encapsulated eplerenone (20 µmol/kg) were administered intraperitoneally (100 μmol lipid per kg) in C57BL/6 mice at the onset of myocardial infarction. Control C57BL/6 mice were injected with equal volumes of plain (MR antagonists lacking) liposome. In additional experimental groups, starting immediately after coronary ligation, C57BL/6 mice were randomly selected for eplerenone (100 mg/kg of body weight) or placebo treatment (5% arabic gum) administered by gavage once daily. Mice subjected to coronary artery ligation were sacrificed at days 1, 3, or 7 after surgery. Mice were excluded from the analyses for 2 reasons: perioperative death (within the first 12 hours after surgery) and MI size <40.
Adult
Animals, Laboratory
antagonists
Artery, Coronary
Body Weight
Eplerenone
Gender
Heart
Ligation
Lipids
Liposomes
Mice, House
Mice, Inbred C57BL
Myocardial Infarction
Operative Surgical Procedures
Placebos
Tube Feeding
Carotid Arteries
Catheters
Dental Anesthesia
Dietary Supplements
Eplerenone
Estrous Cycle
Females
Institutional Animal Care and Use Committees
Isoflurane
Males
Mice, House
Mice, Inbred BALB C
Sodium Chloride
Sodium Chloride, Dietary
Telemetry
Uterus
Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists
Creatinine
Diagnosis
Eplerenone
High Blood Pressures
Hospitalization
Love
Patients
Placebos
Potassium
Serum
We defined the use of MRA (MRA use group) as any new or continued prescription of spironolactone or eplerenone at discharge from the index hospitalization. The detailed definitions of baseline clinical characteristics have been described previously.10 (link)The primary outcome measure was a composite of all-cause death or heart failure hospitalization after discharge from the index hospitalization. Other outcome measures included heart failure hospitalization, all-cause death, cardiovascular death, sudden death, and any-cause hospitalization. Death was regarded as cardiovascular in origin unless obvious noncardiovascular causes could be identified. Cardiovascular death included death related to heart failure, sudden death, death related to stroke, and death from other cardiovascular causes. Sudden death was the unexplained death in a previously stable patient. Stroke was either ischemic or hemorrhagic that required either acute or prolonged hospitalization and had symptoms that lasted more than 24 hours. Heart failure hospitalization was due to worsening of heart failure, requiring intravenous drug therapy.9 (link) Heart failure was classified according to baseline LVEF as with reduced LVEF (<40%) or with preserved LVEF (≥40%).
Laboratory tests were performed on patient admission. Missing laboratory values are presented in eTable 1 in theSupplement .
Laboratory tests were performed on patient admission. Missing laboratory values are presented in eTable 1 in the
Full text: Click here
Cardiovascular System
Cerebrovascular Accident
Congestive Heart Failure
Dietary Supplements
Eplerenone
Hemorrhage
Hospitalization
Patient Admission
Patient Discharge
Patients
Pharmacotherapy
Spironolactone
Sudden Death
Most recents protocols related to «Eplerenone»
All bioinformatics analyses were performed using the software CLC genomic workbench 9.0 (Qiagen, Germantown, MD, USA). Low-quality reads (Q < 20) and read lengths <50 bp were discarded from the raw data. The remaining reads were mapped onto a rainbow trout reference genome (GCA_013265735.3) composed of 71.413 coding sequences using default parameters. Transcripts with absolute fold-change ≥2.0 and an FDR of <0.05 were considered differentially expressed transcripts (DETs) in silico. A comparison between the vehicle and DOC groups considered potential DETs regulated by DOC. Comparisons between the DOC and mifepristone plus DOC groups, as well as the DOC and eplerenone plus DOC groups, considered potential DETs regulated by DOC and mediated by the glucocorticoid and mineralocorticoid receptors, respectively. The identification of gene IDs and DAVID GO enrichment analysis of differentially expressed transcripts were performed using a previously published approximation [20 (link)].
Full text: Click here
Eplerenone
Exons
Genes
Genome
Glucocorticoids
Mifepristone
Mineralocorticoid Receptor
Oncorhynchus mykiss
Juvenile rainbow trout (15.47 g ± 0.88) were obtained from Pisciculture Rio Blanco (Pontificia Universidad Católica de Valparaiso, Valparaíso, Chile). Fish were held under a temperature of 14 ± 1 °C and photoperiod conditions of L/D 12:12. Juvenile fish were fed with Skretting pellets. Fish were sedated with benzocaine (25 mg/L) and intraperitoneally injected with metyrapone (Sigma-Aldrich, St. Louis, MO, USA) (1 mg/kg of fish) for one hour and then divided into different groups. Fish in the first and second groups were treated with vehicle solution (DMSO, PBS 1x) and 11-deoxycorticosterone acetate (DOC, USBiological, Salem, MA, USA), respectively, at physiological concentrations (1 mg/kg). Fish in the third and fourth groups were treated with mifepristone (RU486, Sigma-Aldrich) (1 mg/kg) and mifepristone (1 mg/kg) plus DOC (1 mg/kg), respectively. Finally, fish in the fifth and sixth groups were treated with eplerenone (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1 mg/kg) and eplerenone (1 mg/kg) plus DOC (1 mg/kg), respectively. Three hours after treatment, all rainbow trout (n = 24, four fish per group) were euthanized with benzocaine (Veterquimica, RM, San Bernardo, Chile) (300 mg/L). Heparinized obtained blood was centrifugated at 5000× g for 10 min and the plasma was stored at −80 °C. Myotomal skeletal muscle was isolated from the epaxial area, frozen in liquid nitrogen for 6 h, and then stored at −80 °C.
Full text: Click here
Aftercare
ARID1A protein, human
Benzocaine
BLOOD
Desoxycorticosterone Acetate
Eplerenone
FILIP1L protein, human
Fishes
Freezing
Metyrapone
Mifepristone
Myotomy
Nitrogen
Oncorhynchus mykiss
Pellets, Drug
physiology
Plasma
R-38486
Skeletal Muscles
Sulfoxide, Dimethyl
Skeletal muscle RNA was obtained from all groups: vehicle, DOC, mifepristone, mifepristone plus DOC, eplerenone, and eplerenone plus DOC groups, using an EZNA® Total RNA Kit (OMEGA Bio-Tek Inc., Norcross, GA, USA). Total RNA was quantified with a Qubit RNA BR assay kit (Invitrogen, Waltham, MA, USA). RNA quality was tested with Fragment analyzer systems (Advanced Analytical Technologies, Inc., Ames, IA, USA). Samples with an RNA quality number (RQN) greater than 9 were utilized for library construction. Then, 1 µg of RNA for each sample was used for the construction of 24 cDNA libraries using TruSeq RNA Sample Preparation kit v2 (Illumina, San Diego, CA, USA). All libraries were sequenced (2 × 150 bp) with the Hiseq X Illumina technology in Macrogen (Seoul, Republic of Korea).
Full text: Click here
Biological Assay
cDNA Library
Eplerenone
Mifepristone
Mineralocorticoid Excess Syndrome, Apparent
Skeletal Muscles
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Adrenergic alpha-Antagonists
Adrenergic beta-Antagonists
agonists
Amiloride
Angiotensin-Converting Enzyme Inhibitors
Drug Combinations
Eplerenone
MRAS protein, human
Patients
Pharmaceutical Preparations
Potassium Sparing Diuretics
Prescriptions
Renin Inhibitors
Spironolactone
Thiazides
Triamterene
Vasodilator Agents
At the baseline visit of both the PLACE and SPECTRA trial, demographics and medical history were taken, and an ophthalmologic examination and imaging were performed. This extensive ophthalmologic examination included best-corrected visual acuity in Early Treatment of Diabetic Retinopathy Study letters, and retinal and foveal sensitivity on microperimetry (Macular Integrity Assessment microperimetry, Centervue, Padova, Italy). Imaging included OCT scans, fundus autofluorescence, fundus photographs, fluorescein angiography, ICGA, and were made by certified medical photographers. Patients were randomized to treatment with half-dose PDT or either eplerenone (SPECTRA trial) or high-density subthreshold micropulse laser (PLACE trial). For half-dose PDT, the area to be treated was determined by the central reading center based on hyperfluorescent areas on ICGA compatible with SRF on OCT and leakage on fluorescein angiography.
Before the start of the half-dose PDT, the pupil of the eye to be treated was dilated with topical 1.0% tropicamide and 2.5% phenylephrine. Afterward, 3 mg/m2 body surface verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) was administered over 10 minutes through an intravenous drip. Fifteen minutes after the starting the verteporfin infusion, an anesthetic drop containing oxybuprocaine 0.4% was administered before placing a PDT contact lens (×1.5; Volk Optical, Mentor, OH) on the eye. Finally, half-dose PDT was performed in the target treatment area with a standard fluency of 50 J/cm2, wavelength of 689 nm, and duration of 83 seconds.
At the first visit (6 weeks to 3 months after baseline and treatment) and at the 1-year visit (at 8–12 months after treatment), patients underwent ophthalmologic examination and imaging again. Data of the follow-up at 2 years after the baseline were also collected if present, in most cases, as a final follow-up in the trial setting, but also as a routine follow-up in the clinic.
Before the start of the half-dose PDT, the pupil of the eye to be treated was dilated with topical 1.0% tropicamide and 2.5% phenylephrine. Afterward, 3 mg/m2 body surface verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) was administered over 10 minutes through an intravenous drip. Fifteen minutes after the starting the verteporfin infusion, an anesthetic drop containing oxybuprocaine 0.4% was administered before placing a PDT contact lens (×1.5; Volk Optical, Mentor, OH) on the eye. Finally, half-dose PDT was performed in the target treatment area with a standard fluency of 50 J/cm2, wavelength of 689 nm, and duration of 83 seconds.
At the first visit (6 weeks to 3 months after baseline and treatment) and at the 1-year visit (at 8–12 months after treatment), patients underwent ophthalmologic examination and imaging again. Data of the follow-up at 2 years after the baseline were also collected if present, in most cases, as a final follow-up in the trial setting, but also as a routine follow-up in the clinic.
Aftercare
Anesthetics
benoxinate
Contact Lenses
Diabetic Retinopathy
Eplerenone
Fluorescein Angiography
Human Body
Hypersensitivity
Macula Lutea
Mentors
Neoplasm Metastasis
Patients
Phenylephrine
Pupil
Radionuclide Imaging
Retina
Tropicamide
Verteporfin
Vision
Visual Acuity
Visudyne
Top products related to «Eplerenone»
Sourced in United States
Eplerenone is a laboratory product manufactured by Merck Group. It is a mineralocorticoid receptor antagonist, which means it binds to and blocks the effects of the mineralocorticoid receptor in the body.
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
Sourced in United States, United Kingdom, France, Japan, Switzerland
Aldosterone is a laboratory equipment product designed for the measurement and analysis of aldosterone, a hormone produced by the adrenal glands. The core function of this product is to provide accurate and reliable quantification of aldosterone levels in biological samples, such as blood or urine. This information can be used by healthcare professionals to assess adrenal gland function and investigate conditions related to aldosterone imbalance.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Canada
Mifepristone is a synthetic steroid compound developed by the Roussel Uclaf pharmaceutical company, which was later acquired by Merck Group. It functions as a progesterone receptor antagonist, blocking the action of the natural hormone progesterone.
Sourced in United States, Germany, United Kingdom, Israel, Canada
RU486 is a laboratory product manufactured by Merck Group. It is a synthetic steroid compound used for research purposes. The core function of RU486 is to act as an antiprogesterone agent.
Sourced in United States
Eplerenone is a laboratory equipment product manufactured by Pfizer. It is a selective aldosterone receptor antagonist that functions by blocking the binding of aldosterone to the mineralocorticoid receptor.
Sourced in United States, Germany, France, United Kingdom
Spironolactone is a potassium-sparing diuretic medication manufactured by Merck Group. It is a synthetic steroid compound that inhibits the actions of aldosterone, a hormone involved in the regulation of blood pressure and fluid balance. Spironolactone is used to treat conditions such as heart failure, high blood pressure, and fluid retention.
Sourced in United States, Germany, China, Macao, Sao Tome and Principe, United Kingdom, Japan, Canada, Switzerland, Australia, France
Ang II is a peptide hormone that is involved in the regulation of blood pressure and fluid balance in the body. It is a key component of the renin-angiotensin-aldosterone system (RAAS), which plays a central role in the homeostatic control of blood pressure, fluid, and electrolyte balance. Ang II acts on specific receptors to exert its physiological effects.
Sourced in United States, United Kingdom, Germany, Japan, Sao Tome and Principe, Australia, Brazil, Switzerland, Italy, France, Czechia
Phenylephrine is a pharmaceutical product used as a laboratory reagent. It functions as a sympathomimetic amine, which means it stimulates the sympathetic nervous system. Phenylephrine is commonly used in various research and analytical applications.
Sourced in United Kingdom
Eplerenone is a selective aldosterone blocker developed by Bio-Techne. It is a laboratory product used for research purposes.
More about "Eplerenone"
Eplerenone is a synthetic steroidal antimineralocorticoid agent used to treat hypertension and heart failure.
It selectively blocks the aldosterone receptor, preventing the binding and activation of aldosterone, a hormone that regulates fluid and electrolyte balance.
Eplerenone has been shown to improve survival and reduce the risk of cardiovascular events in patients with left ventricular dysfunction and heart failure following myocardial infarction.
Aldosterone is a mineralocorticoid hormone produced by the adrenal glands that plays a key role in regulating blood pressure and electrolyte balance.
Excessive aldosterone levels can lead to hypertension, fluid retention, and electrolyte imbalances.
Eplerenone works by selectively blocking the aldosterone receptor, preventing aldosterone from binding and exerting its effects.
Other related terms and compounds include dexamethasone, a synthetic glucocorticoid; mifepristone (RU486), a progesterone receptor antagonist; and spironolactone, another antimineralocorticoid.
Angiotensin II (Ang II) is a hormone that can stimulate aldosterone production, and phenylephrine is a vasoconstrictor that can also affect blood pressure regulation.
Using PubCompare.ai, an AI-driven protocol comparison tool, researchers can optimize their Eplerenone-related studies by locating and analyzing relevant protocols from literature, pre-prints, and patents.
This helps ensure reproducibility and identify the best research approaches, taking Eplerenone research to the next level.
It selectively blocks the aldosterone receptor, preventing the binding and activation of aldosterone, a hormone that regulates fluid and electrolyte balance.
Eplerenone has been shown to improve survival and reduce the risk of cardiovascular events in patients with left ventricular dysfunction and heart failure following myocardial infarction.
Aldosterone is a mineralocorticoid hormone produced by the adrenal glands that plays a key role in regulating blood pressure and electrolyte balance.
Excessive aldosterone levels can lead to hypertension, fluid retention, and electrolyte imbalances.
Eplerenone works by selectively blocking the aldosterone receptor, preventing aldosterone from binding and exerting its effects.
Other related terms and compounds include dexamethasone, a synthetic glucocorticoid; mifepristone (RU486), a progesterone receptor antagonist; and spironolactone, another antimineralocorticoid.
Angiotensin II (Ang II) is a hormone that can stimulate aldosterone production, and phenylephrine is a vasoconstrictor that can also affect blood pressure regulation.
Using PubCompare.ai, an AI-driven protocol comparison tool, researchers can optimize their Eplerenone-related studies by locating and analyzing relevant protocols from literature, pre-prints, and patents.
This helps ensure reproducibility and identify the best research approaches, taking Eplerenone research to the next level.